Photo from wikipedia
BACKGROUND c-MET and PI3K pathways are dysregulated in GBM and can drive cancer growth in pre-clinical models. INC280 is a small molecule inhibitor of c-MET; BKM120 is a pan-class I PI3K inhibitor.… Click to show full abstract
BACKGROUND c-MET and PI3K pathways are dysregulated in GBM and can drive cancer growth in pre-clinical models. INC280 is a small molecule inhibitor of c-MET; BKM120 is a pan-class I PI3K inhibitor. A phase Ib/II study was designed to evaluate INC280+BKM120 in patients with recurrent GBM ({"type":"clinical-trial","attrs":{"text":"NCT01870726","term_id":"NCT01870726"}}NCT01870726).
Keywords:
phase;
bkm120;
study;
phase open;
actr phase;
patients recurrent
Journal Title: Neuro-oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Neuro-oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!